Literature DB >> 22351071

Molecular and cellular aspects of mental retardation in the Fragile X syndrome: from gene mutation/s to spine dysmorphogenesis.

Silvia De Rubeis1, Esperanza Fernández, Andrea Buzzi, Daniele Di Marino, Claudia Bagni.   

Abstract

The Fragile X syndrome (FXS) is the most frequent form of inherited mental retardation and also considered a monogenic cause of Autism Spectrum Disorder. FXS symptoms include neurodevelopmental delay, anxiety, hyperactivity, and autistic-like behavior. The disease is due to mutations or loss of the Fragile X Mental Retardation Protein (FMRP), an RNA-binding protein abundant in the brain and gonads, the two organs mainly affected in FXS patients. FMRP has multiple functions in RNA metabolism, including mRNA decay, dendritic targeting of mRNAs, and protein synthesis. In neurons lacking FMRP, a wide array of mRNAs encoding proteins involved in synaptic structure and function are altered. As a result of this complex dysregulation, in the absence of FMRP, spine morphology and functioning is impaired. Consistently, model organisms for the study of the syndrome recapitulate the phenotype observed in FXS patients, such as dendritic spine anomalies and defects in learning. Here, we review the fundamentals of genetic and clinical aspects of FXS, devoting a specific attention to ASD comorbidity and FXS-related diseases. We also review the current knowledge on FMRP functions through structural, molecular, and cellular findings. Finally, we discuss the neuroanatomical, electrophysiological, and behavioral defects caused by FMRP loss, as well as the current treatments able to partially revert some of the FXS abnormalities.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22351071     DOI: 10.1007/978-3-7091-0932-8_23

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  19 in total

1.  Reduced excitatory amino acid transporter 1 and metabotropic glutamate receptor 5 expression in the cerebellum of fragile X mental retardation gene 1 premutation carriers with fragile X-associated tremor/ataxia syndrome.

Authors:  Dalyir I Pretto; Madhur Kumar; Zhengyu Cao; Christopher L Cunningham; Blythe Durbin-Johnson; Lihong Qi; Robert Berman; Stephen C Noctor; Randi J Hagerman; Isaac N Pessah; Flora Tassone
Journal:  Neurobiol Aging       Date:  2013-11-16       Impact factor: 4.673

2.  Fragile X syndrome: causes, diagnosis, mechanisms, and therapeutics.

Authors:  Claudia Bagni; Flora Tassone; Giovanni Neri; Randi Hagerman
Journal:  J Clin Invest       Date:  2012-12-03       Impact factor: 14.808

3.  Alterations in the Sp1 binding and Fmr-1 gene expression in the cortex of the brain during maturation and aging of mouse.

Authors:  Pankaj Gaur; S Prasad
Journal:  Mol Biol Rep       Date:  2014-07-12       Impact factor: 2.316

4.  Development of an expressive language sampling procedure in fragile X syndrome: a pilot study.

Authors:  Elizabeth Berry-Kravis; Emily Doll; Audra Sterling; Sara T Kover; Susen M Schroeder; Shaguna Mathur; Leonard Abbeduto
Journal:  J Dev Behav Pediatr       Date:  2013-05       Impact factor: 2.225

5.  Reciprocal deletion and duplication at 2q23.1 indicates a role for MBD5 in autism spectrum disorder.

Authors:  Sureni V Mullegama; Jill A Rosenfeld; Carmen Orellana; Bregje W M van Bon; Sara Halbach; Elena A Repnikova; Lauren Brick; Chumei Li; Lucie Dupuis; Monica Rosello; Swaroop Aradhya; D James Stavropoulos; Kandamurugu Manickam; Elyse Mitchell; Jennelle C Hodge; Michael E Talkowski; James F Gusella; Kory Keller; Jonathan Zonana; Stuart Schwartz; Robert E Pyatt; Darrel J Waggoner; Lisa G Shaffer; Angela E Lin; Bert B A de Vries; Roberto Mendoza-Londono; Sarah H Elsea
Journal:  Eur J Hum Genet       Date:  2013-05-01       Impact factor: 4.246

6.  FMRP targets distinct mRNA sequence elements to regulate protein expression.

Authors:  Manuel Ascano; Neelanjan Mukherjee; Pradeep Bandaru; Jason B Miller; Jeffrey D Nusbaum; David L Corcoran; Christine Langlois; Mathias Munschauer; Scott Dewell; Markus Hafner; Zev Williams; Uwe Ohler; Thomas Tuschl
Journal:  Nature       Date:  2012-12-12       Impact factor: 49.962

Review 7.  Consolidation and translation regulation.

Authors:  Shunit Gal-Ben-Ari; Justin W Kenney; Hadile Ounalla-Saad; Elham Taha; Orit David; David Levitan; Iness Gildish; Debabrata Panja; Balagopal Pai; Karin Wibrand; T Ian Simpson; Christopher G Proud; Clive R Bramham; J Douglas Armstrong; Kobi Rosenblum
Journal:  Learn Mem       Date:  2012-08-16       Impact factor: 2.460

8.  VolRoverN: enhancing surface and volumetric reconstruction for realistic dynamical simulation of cellular and subcellular function.

Authors:  John Edwards; Eric Daniel; Justin Kinney; Tom Bartol; Terrence Sejnowski; Daniel Johnston; Kristen Harris; Chandrajit Bajaj
Journal:  Neuroinformatics       Date:  2014-04

Review 9.  Intellectual disability: dendritic anomalies and emerging genetic perspectives.

Authors:  Tam T Quach; Harrison J Stratton; Rajesh Khanna; Pappachan E Kolattukudy; Jérome Honnorat; Kathrin Meyer; Anne-Marie Duchemin
Journal:  Acta Neuropathol       Date:  2020-11-23       Impact factor: 17.088

10.  The PAKs come of age: Celebrating 18 years of discovery.

Authors:  Jeffrey Field; Ed Manser
Journal:  Cell Logist       Date:  2012-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.